Asthma stepwise management acc to GINA guidelines
Reading File
Finding Sources
Finding Sources
Searching the Web
GINA 2024 2025 asthma stepwise management guidelines steps
Finding Sources
Reading Web Page
GINA asthma stepwise management steps track 1 track 2
Searching PubMed
"asthma" AND "GINA" AND "stepwise management"
Finding Sources
Searching Images
GINA asthma stepwise management treatment steps diagram
Loading Image
Reading Web Page
GINA 2025 asthma step 5 severe asthma biologics add-on therapy children 6-11
Here is a comprehensive overview of GINA 2025 Asthma Stepwise Management — the most current update as of May 2025.
GINA 2025: Asthma Stepwise Management
Core Framework: Personalised Asthma Management
GINA uses an Assess → Adjust → Review cycle tailored to individual patient needs. The guiding principle is that no patient should be on SABA alone — all patients need an ICS-containing reliever or controller.
Adults & Adolescents (≥12 years) — 5-Step Approach
GINA 2025 retains the two-track system introduced in 2020–21:
| Track 1 (PREFERRED) | Track 2 (Alternative) | |
|---|---|---|
| Reliever | Low-dose ICS-formoterol (as-needed) | SABA (but check adherence first) |
| Advantage | Single inhaler across Steps 1–4; ↓65% emergency visits vs SABA alone | Accessible in low/middle-income settings |
| Note | Reduces severe exacerbations significantly | Medium-to-high dose ICS-LABA changed to medium-dose at Step 4 in 2025 update |
Track 1 Steps (Preferred)
| Step | Controller | Reliever | Notes |
|---|---|---|---|
| Step 1 | None | Low-dose ICS-formoterol as-needed | For infrequent symptoms; no daily controller needed |
| Step 2 | None | Low-dose ICS-formoterol as-needed | For mild persistent symptoms; still as-needed only |
| Step 3 | Low-dose ICS-formoterol (daily maintenance) | Low-dose ICS-formoterol as-needed | MART begins (Maintenance And Reliever Therapy) |
| Step 4 | Medium-dose ICS-formoterol (daily maintenance) | Low-dose ICS-formoterol as-needed | MART continues; e.g., Symbicort 200/6 |
| Step 5 | Medium-dose ICS-formoterol + add-ons | Low-dose ICS-formoterol as-needed | Add LAMA (tiotropium); refer for phenotype/biologic assessment |
MART uses ICS-formoterol as both controller and reliever. This works because formoterol is a fast-onset LABA. ICS-LABA inhalers without formoterol cannot be used as MART.
Track 2 Steps (Alternative)
| Step | Controller | Reliever |
|---|---|---|
| Step 1 | None (but take low-dose ICS with each SABA dose) | SABA |
| Step 2 | Low-dose ICS daily | SABA |
| Step 3 | Low-dose ICS-LABA (e.g., Seretide 50 Evohaler) | SABA |
| Step 4 | Medium-dose ICS-LABA (changed in 2025 from medium-to-high) | SABA |
| Step 5 | As per Step 5 above; add-on LAMA, biologics | SABA |
Step 5 — Severe Asthma Management
If uncontrolled despite Step 4, refer to specialist. Investigations include:
- Blood eosinophil count (BEC) and FeNO — T2 biomarkers (measure ≥3 times if initially below threshold)
- Assess comorbidities, inhaler technique, adherence
Add-on options:
| Biologic | Target | Indication |
|---|---|---|
| Anti-IgE (omalizumab) | IgE | Allergic asthma |
| Anti-IL5/5R (mepolizumab, benralizumab) | Eosinophilic inflammation | Eosinophilic asthma |
| Anti-IL4Rα (dupilumab) | IL-4/IL-13 | T2 asthma |
| Anti-TSLP (tezepelumab) | TSLP | Broad T2 asthma |
| LAMA (tiotropium) | Muscarinic | Add-on at all severe steps |
Children 6–11 Years
A single track approach (no ICS-formoterol MART):
| Step | Controller | Reliever |
|---|---|---|
| Step 1 | None | SABA (+ low-dose ICS simultaneously) |
| Step 2 | Low-dose ICS daily | SABA |
| Step 3 | Low-dose ICS-LABA or medium-dose ICS | SABA |
| Step 4 | Medium-dose ICS-LABA | SABA |
| Step 5 | High-dose ICS-LABA; refer for biologic assessment | SABA |
Second-line controller at any step: LTRA (montelukast)
Children ≤5 Years
- Diagnosis is clinical (no spirometry possible)
- Step 1–2: As-needed SABA ± low-dose ICS trial
- Step 3: Daily low-dose ICS; LTRA as alternative
- Step 4: Refer to specialist; medium-dose ICS or add LTRA
- Biologics generally not recommended in this age group
Key GINA 2025 Updates (vs. Prior Years)
| Change | Detail |
|---|---|
| Track 2, Step 4 | Changed from medium-to-high dose ICS-LABA → medium-dose ICS-LABA only (minimise high-dose ICS adverse effects) |
| T2 biomarkers | Updated guidance on BEC/FeNO interpretation; measure ≥3× before deciding on biologics |
| Severe asthma decision tree | Diagnosis confirmation moved to Stage 5 of specialist workup |
| Young children exacerbations | Nebulised albuterol dose clarified: 2.5 mg (not 0.25 mg) for ≤5 years |
| Non-pharmacologic strategies | Smoking cessation, physical activity, weight reduction, vaccinations, HDM SLIT allergen immunotherapy |
ICS Dose Categories (BDP-equivalent, adults ≥12 yrs)
| Category | Dose (mcg/day) |
|---|---|
| Low | ≤250 |
| Medium | 251–500 |
| High | >500 |
2021 Asthma Management Continuum Diagram
The continuum above (from the textbook library) illustrates the escalating stepwise approach — from foundational environmental control and diagnosis confirmation, through ICS escalation, up to add-on LABA/LTRA/tiotropium and biologic therapy for severe disease.
Sources: GINA 2025 Summary Guide | GINA 2025 Update Overview | Medical Textbook Library (Harriet Lane Handbook, 23rd ed.)
This is a shared conversation. Sign in to Orris to start your own chat.